Romosozumab increases spine bone density in a human trial; independent labs link it with higher bone density and lower mortality in osteoporosis. Cardiovascular associations point both ways, including higher stroke risk with prior cardiovascular history. Most trials for non-aging uses are sponsored by Amgen and UCB Biopharma; a trial ended over a year ago without posted results.
61 findings in 29 papers from 2020 to 2026, 15 of them since April 2026
Independent labs found the same change in people. 18 independent labs in 6 countries; 35 trials, none about aging, 1 with no results posted.
“they did not differ significantly between the romosozumab and placebo groups over weeks 6 to 20 (p = 0.198)”
Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
18 independent labs in 6 countries
2 findings against
35 trials, none about aging, 1 with no results posted
Funders: Amgen and others
3 of 43 findings with company ties
23 of 35 trials sponsored by its developers
Human trial4
Humans15
Animals4
Studies in people
2 studies gave romosozumab to people and measured what changed.
↔no change: Has no effect on time to radiographic fracture healing16.4 to 16.9 weeks across treatment groups
↔no change: Has no effect on Radiographic Union Scale for Hip
Randomized trialweeks 6 to 20
332 people55 to 94 yearsOlder adults; open reduction and internal fixation of intertrochanteric or femoral neck hip fractures
The Journal of bone and joint surgery. American volume, Jan 22, 2020
What did studies of romosozumab find?
34
Studies of romosozumab measured 34 outcomes; the most studied are mortality (4 studies), bone fracture (2) and bone mineral density (2).
Mortality
↓downin humans4HR 0.554–0.68
4 studies
Romosozumab is linked with lower mortality in humans (compared with teriparatide/abaloparatide in osteoporosis).
“Romosozumab participants continued to demonstrate a significantly lower hazard (and improved survival probabilities) of myocardial infarction, heart failure, and death”
Humanscompared with teriparatide/abaloparatide in osteoporosis1 year
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·
Bone fracture
↓downin humans2
2 studies
Romosozumab protects against bone fracture in humans.
Romosozumab prevents bone fracture in humans (followed by an anti-resorptive).
“Romosozumab is given as monthly s.c. injections for 1 year, followed by an anti-resorptive. This sequence prevents more fractures than anti-resorptive therapy alone.”
Romosozumab increases lumbar spine bone mineral density in humans (versus denosumab) (+13.7% vs. +8.5%).
“The primary outcome of the study was the percentage change in LS-BMD at 12 months, which was significantly greater in the romosozumab group (13.7% [10.8–16.7]) than in the denosumab group (8.5% [6.5–10.5]; p = 0.0035) (Fig. (a)).”
Human trialversus denosumab12 monthsfemalesn = 112
Romosozumab increases lumbar spine bone mineral density in humans (primary osteoporosis and knee osteoarthritis) (13.7% vs 8.5%, p = 0.0035).
“The mean percentage change in LS-BMD at 12 months was significantly higher in the romosozumab group (13.7%) than in the denosumab group (8.5%; p = 0.0035).”
Human trialprimary osteoporosis and knee osteoarthritislumbar spine12 monthsfemales
Romosozumab was not clearly linked with antidiabetic medication initiation in humans (Patients with osteoporosis and no prior diabetes; compared with denosumab) (HR 1.15, 95% CI 0.95–1.40).
“Similarly, no significant differences were observed for broader diabetes diagnoses (HR, 1.01; 95% CI, 0.86–1.20), antidiabetic medication initiation (HR, 1.15; 95% CI, 0.95–1.40)”
HumansPatients with osteoporosis and no prior diabetes; compared with denosumabn = 6,581
Romosozumab was not clearly linked with incident type 2 diabetes in humans (Patients with osteoporosis and no prior diabetes; compared with denosumab) (HR 0.93, 95% CI 0.78–1.12; log-rank p = 0.468).
“Romosozumab initiation was not associated with a significant difference in incident T2D compared with denosumab”
HumansPatients with osteoporosis and no prior diabetes; compared with denosumabn = 6,581
Romosozumab is linked with higher alveolar bone mineral density in humans (osteoporosis).
“During sequential bone-anabolic therapy, al-BMD significantly increased over time, eventually reaching levels comparable to those of elderly non-osteoporotic controls.”
Romosozumab showed no clear effect on time to radiographic fracture healing in humans (hip fracture surgery) (16.4 to 16.9 weeks across treatment groups).
“The median time to radiographic evidence of healing was 16.4 to 16.9 weeks across treatment groups.”
Human trialhip fracture surgeryhip70, 140, or 210 mgn = 332
The Journal of bone and joint surgery. American volume·
Timed Up and Go test
↔no changein humans1
1 study
Romosozumab showed no clear effect on timed Up and Go test in humans (open reduction and internal fixation of intertrochanteric or femoral neck hip fractures) (p = 0.198).
“they did not differ significantly between the romosozumab and placebo groups over weeks 6 to 20 (p = 0.198)”
Human trialopen reduction and internal fixation of intertrochanteric or femoral neck hip fractures70, 140, or 210 mgweeks 6 to 20n = 332
Romosozumab lowers the risk of bone fracture in humans (Postmenopausal women at high fracture risk; compared with alendronate).
“reduces fracture risk more rapidly and more effectively than alendronate, with persisting effects for at least two years after transition to antiresorptive agents.”
ReviewPostmenopausal women at high fracture risk; compared with alendronatebonefemales
Romosozumab is linked with a lower risk of heart failure in humans (compared with teriparatide/abaloparatide in osteoporosis).
“Romosozumab participants continued to demonstrate a significantly lower hazard (and improved survival probabilities) of myocardial infarction, heart failure, and death”
Humanscompared with teriparatide/abaloparatide in osteoporosis1 year
Romosozumab is linked with a lower risk of major adverse cardiovascular events in humans (compared with teriparatide/abaloparatide in osteoporosis) (HR 0.624, 95% CI 0.567-0.688).
“We observed a significant association with lower hazard ratios among four- (HR 0.441, 95% CI 0.0.376-0.638, p < 0.0001) and three-point major adverse cardiovascular events (HR 0.624, 95% CI 0.567-0.688, p < 0.0001)”
Humanscompared with teriparatide/abaloparatide in osteoporosis1 year
Romosozumab raises the risk of major adverse cardiovascular events in humans (particularly in patients with pre-existing cardiovascular conditions).
“However, clinical trials report an increased incidence of major adverse cardiovascular events (MACE), particularly in patients with pre-existing cardiovascular conditions”
Reviewparticularly in patients with pre-existing cardiovascular conditions
Romosozumab is linked with a lower risk of cardiovascular disease in humans (without a prior cardiovascular history) (HR 0.645, 95% CI 0.438-0.950).
“romosozumab was associated with significantly lower risks of 3P-MACE at 3-year (hazard ratio (HR) 0.645, 95% confidence interval (CI) 0.438-0.950, p = 0.023)”
Humanswithout a prior cardiovascular history3 years
Romosozumab is linked with a lower risk of cardiovascular disease in humans (chronic kidney disease) (12.6% vs. 18.8%; RR, 0.668 [95% CI, 0.553-0.808]).
“Romosozumab was associated with lower 1095-day cumulative risk of the composite cardiovascular outcome than denosumab (12.6% vs. 18.8%; RR, 0.668 [95% CI, 0.553-0.808])”
Humanschronic kidney disease1095 days94.9% and 93.8% womens
Romosozumab is linked with a lower risk of myocardial infarction in humans (compared with teriparatide/abaloparatide in osteoporosis).
“Romosozumab participants continued to demonstrate a significantly lower hazard (and improved survival probabilities) of myocardial infarction, heart failure, and death”
Humanscompared with teriparatide/abaloparatide in osteoporosis1 year
Romosozumab is linked with a higher risk of chronic ischemic heart disease in humans with a prior cardiovascular history.
“romosozumab was associated with significantly higher risks of 4P-MACE, 5P-MACE, stroke, mortality, and chronic ischemic heart disease across all three follow-up time horizons.”
Romosozumab is linked with a higher risk of stroke in humans with a prior cardiovascular history.
“among patients with a prior cardiovascular history, romosozumab was associated with significantly higher risks of 4P-MACE, 5P-MACE, stroke, mortality, and chronic ischemic heart disease”
Romosozumab is linked with a lower risk of Alzheimer's disease in humans (compared with teriparatide initiation, 1-year per-protocol analysis) (RR 0.77 (95% CI, 0.65 to 0.86)).
“For Alzheimer's disease specifically, the ARR was 0.6% (95% confidence interval, 0.3 to 0.9%), with an RR of 0.77 (95% confidence interval, 0.65 to 0.86).”
Humanscompared with teriparatide initiation, 1-year per-protocol analysis1-year
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·
Romosozumab is linked with a lower risk of dementia in humans (compared with teriparatide initiation, 1-year per-protocol analysis) (RR 0.76 (95% CI, 0.69 to 0.82)).
“In the 1-year per-protocol analyses, the ARR was 1.0% (95% confidence interval, 0.7 to 1.4%), with a RR of 0.76 (95% confidence interval, 0.69 to 0.82).”
Humanscompared with teriparatide initiation, 1-year per-protocol analysis1-year
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·
In humans with osteoporosis, romosozumab increases lumbar spine and alveolar bone mineral density. A human study also reports reduced TRACP-5b and P1NP levels following monthly subcutaneous treatment.
The hazard ratio for type 2 diabetes, comparing risk over time, was 0.93 for romosozumab versus denosumab, with no statistically clear difference.The hazard ratio for type 2 diabetes, comparing risk over time, was 0.93 for romosozumab versus denosumab, with no statistically clear difference.